webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Pyrrolobenzodiazepines

Products Catalog Download PDF

Pyrrolobenzodiazepines (PBDs) are well known naturally occurring DNA interactive antitumour antibiotics like anthramycin, chicamycin and DC-81, which are produced from various Streptomyces bacteria. This natural product was shown to be significantly cytotoxic toward tumour cells in vitro. Meanwhile, PBDs-dimers are DNA alkylators that exhibit extremely potent cytotoxic activities against multiple cancer cell lines. These molecules function by covalently binding to the 2-amino groups of guanine in the minor grooves of cellular DNA, thereby forming DNA adducts that disrupt normal cell functions.

Category
By SubCategory
By Functional Group
By Formula Weight
Filtered by
Clear All
Background
Why BOC Sciences

Comprehensive one-stop antibody-drug conjugate service platform

Large Stock

More than 1000+ high-purity products in inventory

Large Stock

Global Delivery

Warehouses in multiple cities to ensure fast delivery

Large Stock

mg to kg

Qualified facilities & equipment of cGMP laboratory

mg to kg

24/7 Technical Support

Strict process parameter control to ensure product quality

Large Stock

Chemical Structural Characteristics of Pyrrolobenzodiazepines

Pyrrolobenzodiazepines (PBDs) are all tricyclic systems consisting of an aromatic A-ring, a 1-4-diazepin-5-one B-ring and a pyrrolidine C-ring, which differ from one another principally by the position and type of substituents in the A- and C-rings, and the degree and position of points of unsaturation in the C-ring. All the naturally occurring compounds possess the S-configuration at C11a which results in a right-handed helical conformation allowing them to fit perfectly in the minor groove of DNA.

Mechanism of Action of Pyrrolobenzodiazepines

Pyrrolobenzodiazepine’s biological activity through covalent binding via their N10–C11 imine/carbinolamine moiety to the C2-amino position of a guanine residue within the minor groove of duplex DNA. PBDs monomers span three DNA base pairs with a preference for 50-Pu-G-Pu, particularly 50-AG or 50-GA sequences. The cytotoxicity of these agents is thought to be due to their ability to inhibit cellular processes such as replication and transcription. PBDs-dimers can form interstrand and intrastrand DNA cross-links as well as mono-alkylated DNA adducts, and are significantly more cytotoxic than PBD monomers such as anthramycin, a characteristic attributed to their ability to cross-link DNA.

Application of Pyrrolobenzodiazepines

Since the discovery of the pyrrolobenzodiazepines in 1965, examples of both PBD monomers (anthramycin, tomaymycin, neothramycin and sibiromycin) and a PBD dimer (SJG-136) have been evaluated in the clinic as single-agent anticancer agents. Due to their exquisite cytotoxicity in tumour cell lines, PBD dimers were first evaluated as ADC payloads in the late 2000s. The first conjugates to reach the clinic were rovalpituzumab tesirine (Rova-T), targeted to DLL3 (Cancer Stem Cell-Associated Target Delta-Like Protein 3) for lung cancer, and vadastuximab talirine (SGN-CD33A), targeted to CD33 (SIGLEC-3, a transmembrane receptor expressed on cells of myeloid lineage) for acute myeloid leukaemia (AML). Since then, a number of other ADCs containing a PBD dimer payload have entered the clinic. The linker-payload Tesirine (SG3249) incorporating the payload SG3199 is the construct of choice for several ADCs including rovalpituzumab tesirine, ADCT-301, ADCT-402, ADCT-601, ADCT-602, MEDI7247 and MEDI3726 which are all currently at different stages of clinical development.

References

  1. Kamal, A.; et al. Synthesis and potential cytotoxic activity of new phenanthrylphenol-pyrrolobenzodiazepines. European Journal of Medicinal Chemistry, 2010, 45: 2173-2181.
  2. Hartley; J.A. The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin. Investig. Drugs, 2011, 20(6): 733-744.
* Only for research. Not suitable for any diagnostic or therapeutic use.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Purity Guaranteed

≥95%
Purity Guaranteed

Countries/Regions Delivered

20+
Countries/Regions Delivered

Technical Support

24/7
Technical Support

Products In Stock

1,000+
Products In Stock

High-Quality Service

100%
High-Quality Service
Send Inquiry
Verification code
Inquiry Basket